Wells Fargo’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.59K | Buy |
3,260
+391
| +14% | +$464 | ﹤0.01% | 6284 |
|
|
2026
Q1 | $4.99K | Buy |
2,869
+125
| +5% | +$206 | ﹤0.01% | 6120 |
|
|
2025
Q4 | $4.78K | Buy |
2,744
+2,528
| +1,170% | +$5.57K | ﹤0.01% | 6105 |
|
|
2025
Q3 | $505 | Sell |
216
-751
| -78% | -$1.44K | ﹤0.01% | 6292 |
|
|
2025
Q2 | $1.97K | Sell |
967
-21,402
| -96% | -$41K | ﹤0.01% | 6218 |
|
|
2025
Q1 | $36.5K | Buy |
22,369
+5,681
| +34% | +$11.4K | ﹤0.01% | 5494 |
|
|
2024
Q4 | $30.5K | Buy |
16,688
+3,238
| +24% | +$14.3K | ﹤0.01% | 5638 |
|
|
2024
Q3 | $77.7K | Buy |
13,450
+333
| +3% | +$2.75K | ﹤0.01% | 5156 |
|
|
2024
Q2 | $106K | Buy |
13,117
+11,618
| +775% | +$122K | ﹤0.01% | 4908 |
|
|
2024
Q1 | $20.8K | Sell |
1,499
-322
| -18% | -$2.78K | ﹤0.01% | 5567 |
|
|
2023
Q4 | $11.1K | Buy |
1,821
+261
| +17% | +$1.29K | ﹤0.01% | 5806 |
|
|
2023
Q3 | $7.28K | Sell |
1,560
-165
| -10% | -$911 | ﹤0.01% | 5874 |
|
|
2023
Q2 | $9.24K | Sell |
1,725
-35,217
| -95% | -$284K | ﹤0.01% | 5924 |
|
|
2023
Q1 | $364K | Buy |
36,942
+35,307
| +2,159% | +$602K | ﹤0.01% | 4054 |
|
|
2022
Q4 | $30.6K | Sell |
1,635
-1,269
| -44% | -$28.8K | ﹤0.01% | 5083 |
|
|
2022
Q3 | $60K | Sell |
2,904
-497
| -15% | -$12.7K | ﹤0.01% | 4865 |
|
|
2022
Q2 | $71K | Sell |
3,401
-4,816
| -59% | -$136K | ﹤0.01% | 4847 |
|
|
2022
Q1 | $354K | Sell |
8,217
-11,947
| -59% | -$538K | ﹤0.01% | 4645 |
|
|
2021
Q4 | $1.21M | Buy |
20,164
+3,859
| +24% | +$309K | ﹤0.01% | 3976 |
|
|
2021
Q3 | $1.4M | Buy |
16,305
+5,731
| +54% | +$575K | ﹤0.01% | 3950 |
|
|
2021
Q2 | $1.18M | Buy |
10,574
+581
| +6% | +$55.8K | ﹤0.01% | 4098 |
|
|
2021
Q1 | $1.11M | Sell |
9,993
-24,764
| -71% | -$3.26M | ﹤0.01% | 4169 |
|
|
2020
Q4 | $3.69M | Buy |
34,757
+2,366
| +7% | +$315K | ﹤0.01% | 3010 |
|
|
2020
Q3 | $4.51M | Sell |
32,391
-2,016
| -6% | -$420K | ﹤0.01% | 2609 |
|
|
2020
Q2 | $11.1M | Buy |
34,407
+27,583
| +404% | +$4.43M | ﹤0.01% | 1773 |
|
|
2020
Q1 | $609K | Buy |
6,824
+65
| +1% | +$4.01K | ﹤0.01% | 3895 |
|
|
2019
Q4 | $268K | Sell |
6,759
-9,551
| -59% | -$287K | ﹤0.01% | 4791 |
|
|
2019
Q3 | $401K | Buy |
16,310
+552
| +4% | +$16.8K | ﹤0.01% | 4523 |
|
|
2019
Q2 | $556K | Sell |
15,758
-6,092
| -28% | -$242K | ﹤0.01% | 4304 |
|
|
2019
Q1 | $978K | Buy |
21,850
+7,892
| +57% | +$398K | ﹤0.01% | 3895 |
|
|
2018
Q4 | $670K | Buy |
13,958
+7,465
| +115% | +$453K | ﹤0.01% | 4143 |
|
|
2018
Q3 | $434K | Buy |
6,493
+199
| +3% | +$11.1K | ﹤0.01% | 4536 |
|
|
2018
Q2 | $296K | Sell |
6,294
-8,862
| -58% | -$489K | ﹤0.01% | 4812 |
|
|
2018
Q1 | $857K | Buy |
15,156
+239
| +2% | +$12.9K | ﹤0.01% | 4024 |
|
|
2017
Q4 | $739K | Buy |
14,917
+6,277
| +73% | +$389K | ﹤0.01% | 4118 |
|
|
2017
Q3 | $657K | Buy |
8,640
+1,195
| +16% | +$88.9K | ﹤0.01% | 4143 |
|
|
2017
Q2 | $701K | Sell |
7,445
-2,935
| -28% | -$251K | ﹤0.01% | 3994 |
|
|
2017
Q1 | $825K | Buy |
10,380
+2,324
| +29% | +$185K | ﹤0.01% | 3884 |
|
|
2016
Q4 | $671K | Buy |
8,056
+1,213
| +18% | +$110K | ﹤0.01% | 4001 |
|
|
2016
Q3 | $765K | Buy |
6,843
+16
| +0.2% | +$1.77K | ﹤0.01% | 3681 |
|
|
2016
Q2 | $757K | Buy |
6,827
+208
| +3% | +$25.3K | ﹤0.01% | 3667 |
|
|
2016
Q1 | $693K | Buy |
6,619
+573
| +9% | +$44.2K | ﹤0.01% | 3650 |
|
|
2015
Q4 | $487K | Buy |
6,046
+573
| +10% | +$45.6K | ﹤0.01% | 3940 |
|
|
2015
Q3 | $379K | Sell |
5,473
-24
| -0.4% | -$2.09K | ﹤0.01% | 4118 |
|
|
2015
Q2 | $538K | Buy |
5,497
+1,450
| +36% | +$155K | ﹤0.01% | 4044 |
|
|
2015
Q1 | $396K | Buy |
4,047
+3,814
| +1,637% | +$370K | ﹤0.01% | 4084 |
|
|
2014
Q4 | $26K | Sell |
233
-39
| -14% | -$4.77K | ﹤0.01% | 5256 |
|
|
2014
Q3 | $32K | Sell |
272
-427
| -61% | -$53.2K | ﹤0.01% | 5109 |
|
|
2014
Q2 | $90K | Buy |
699
+149
| +27% | +$17.6K | ﹤0.01% | 4723 |
|
|
2014
Q1 | $88K | Buy |
+550
| New | +$78.9K | ﹤0.01% | 4709 |
|
Other funds holding INO
JT
BCM
ACM
EP
Wells Fargo's INO Position: Q2 2026 in Review
Wells Fargo increased its Inovio Pharmaceuticals (INO) stake by 14% in Q2 2026, buying an estimated $464 and bringing the position to 3,260 shares worth $3.59K. The position accounts for ﹤0.01% of the portfolio, ranked #6284.
Wells Fargo first reported a position in INO in Q1 2014 and has held it in 50 quarters since. The position peaked at $11.1M in Q2 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.
- Wells Fargo held 3,260 shares of Inovio Pharmaceuticals worth $3.59K as of Q2 2026.
- Wells Fargo bought 391 Inovio Pharmaceuticals shares in Q2 2026, an estimated $464.
- Inovio Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6284 holding.
- Wells Fargo first reported a position in Inovio Pharmaceuticals in Q1 2014 and has held it in 50 quarters since.
- Wells Fargo's Inovio Pharmaceuticals position peaked at $11.1M in Q2 2020.
- 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.